Immunotherapy has emerged in recent years as an effective novel treatment for lymphoma, with studies constantly striving to identify new molecules that could help patients. Here, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the current state of lymphoma immunotherapy research, including follow-up data on the efficacy of rituximab, and information on several newer treatments, such as ADCC-activating monoclonal antibodies and antibody-drug conjugates. Dr Collins also discusses some of the most exciting data yet to be released in the field, such as that from the ECHELON-1 trial and the use of CAR T-cells in lymphoma. This feature was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.
The post Revolutionary immunotherapies for lymphoma appeared first on VJHemOnc.
